方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 卫生经济学中的决策分析模型× | 成本-效益分析 (CEA)× | |
|---|---|---|
| 领域 | 卫生经济学 | 卫生经济学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1975 | 1984 |
| 提出者≠ | Pauker & Kassirer (medical decision analysis, Massachusetts General Hospital) | Drummond & Stoddart (Health Economics Research Group, McMaster University) |
| 类型 | Method | Method |
| 开创性文献≠ | Pauker, S. G., & Kassirer, J. P. (1975). Therapeutic Decision Making: A Cost-Benefit Analysis. New England Journal of Medicine, 293(5), 229-234. DOI ↗ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ |
| 别名≠ | decision analysis, decision tree, decision model, health economic model | CEA, ICER, Incremental Cost-Effectiveness Ratio |
| 相关 | 5 | 5 |
| 摘要≠ | Decision analytic modeling is a systematic framework for comparing health interventions by integrating evidence on probabilities, outcomes, costs, and patient preferences into a quantitative model. Developed by Pauker and Kassirer in 1975, decision analysis structures clinical uncertainty and economic trade-offs, enabling transparent comparison of treatment options and identification of optimal strategies. Used in health technology assessment, clinical practice guideline development, and resource allocation decisions. | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. |
| ScholarGate数据集 ↗ |
|
|